European Medicines Agency concludes that benefit-risk balance of angiotensin II receptor antagonists remains positive (EMA press release, 20 October 2011)

Burden of osteoporotic fractures increases dramatically in the Middle East and Africa (EurekAlert, 22 October 2011)

European Medicines Agency starts review of Protelos / Osseor (EMA press release, 20 October 2011)

24 Oct 2011

The European Medicines Agency will review the strontium-ranelate-containing osteoporosis medicines Protelos and Osseor to determine whether cardiovascular and cutaneous adverse reactions reported in a French study have an impact on their benefit-risk profile and conditions of use.

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read